Search

Lercanidipine is an antihypertensive drug. It is a dihydropyridine class of calcium channel blockers. It is extremely bitter. The reason for this exploration was to build up a non-bitter orally breaking down the tablet of inadequately solvent medication viz Lercanidipine. The bitterness of drug, masked through complexing Tulsion 339 in various ratios. Sodium starch glycolate, crospovidone, low substituted hydroxypropyl cellulose selected as super disintegrants in the formulation. The formulated tablets were assessed for various properties like Drug content, crushing strength, friability, wetting time, water retention proportion, breaking downtime and in-vitro disintegration time and dissolution studies. The disintegration time obtained in the range between 38.46-51.40 seconds. Release studies observed between 5 to 30 minutes. From the prepared formulations, formulation using Low substituted hydroxypropyl cellulose with 5% concentration showed 98.89% drug release within 30minutes. Thus F9 was considered as best among the other formulations With effective dissolution and improves patient intake. Drug release Kinetic analysis (r2) based on best curve fitting method for optimized lercandipine formulation showed first order kinetics proves that the drug release depends upon its concentration.

A simple, convenient, specific, precise and highly conventional stability-indicating ultra-performance liquid chromatographic‑ diode array method was developed for the quantification of Apalutamide in human plasma. The Phenomenex Luna (100x4.6x5µ) column was used for apalutamide separation. The mobile phase was composed with 5 mM ammonium fumarate and acetonitrile in the ratio of 15:85 v/v, and buffer pH 3.5 was adjusted with glacial acetic acid and detected at 345 nm. The Apalutamide‑D3 used as internal standard and K2‑EDTA used as a coagulant. The liquid-liquid extraction process used for extraction of drug from human plasma with tert butyl methyl ether. The retention times of Apalutamide and Apalutamide D3 (ISTD) was 1.48 min & 1.97 min, respectively. The assay of the method was validated in human plasma in the concentration range from 307.26-200013.87 pg/ml with the accuracy and precision ranging from 3.86 to 4.87. Recovery studies were found to be 103.79%, 90.93% & 96.83% for HQC, MQC and LQC respectively. The stability of the drug was evaluated in human plasma with different conditions of the auto-sampler, freeze-thaw, bench top, short term and long term stability studies were performed. The method was proved as highly sensitive and selective for the quantification of Apalutamide and determined at the picogram level. There was no matrix effect observed and proved as a stability-indicating method.

The current papers offer the formulation, optimization, and evaluation of the starch-based in-situ gelling system of Cimetidine. The objective of the present study was to optimize the concentration of starch and concentration of MgCl2for the formulation of in-situ gels of Cimetidine. Starch based in-situ gels of Cimetidine were subjected to measurement of viscosity, pH, drug content, and Q80. Entirely the preliminary batches were prepared by using different concentrations of sodium alginate (0.5% - 2%) and a constant concentration of MgCl2. On source the preliminary Screening, a 32full factorial pattern set about to review the consequence containing self-sustaining variables, Put concentration Containing starch (X1) and concentration containing MgCl2(X2) as to apprenticed probabilities like viscosity, drug content, Q80,and similarity factor. The best formulation C9 exhibited optimum viscosity (316 cp), drug content (99.25%), Q80(90.15%), and similarity factor (73.46). The best batch exhibited good water uptake (62.44%) and there were no interactions were found during the IR study. A slow release of Cimetidine was observed and a good fit to the Korsmeyer Peppas plots was demonstrated. The correlation coefficient of the best batch is 0.9973 (Korsmeyer Peppas plots).

Carbon tetrachloride (CCl4) is a well-known hepatotoxin and exposure to this chemical is known to induce oxidative stress and causes liver injury by the formation of free radicals. Flacourtia indica commonly known as 'Baichi' has been reported as an effective remedy for the treatment of a variety of diseases. The objective of this study was to investigate the hepatoprotective activity of aqueous extract of leaves of Flacourtia indica against CCl4 induced hepatotoxicity. Animals were pretreated with the aqueous extract of Flacourtia indica (250 & 500 mg/kg body weight) for one week and then challenged with CCl4 (1.5 ml/kg bw) in olive oil (1:1, v/v) on 7th day. Serum marker enzymes (ALP, AST, ALT, Total Protein & Total Bilirubin) and TBARS level (Marker for oxidative stress) were estimated in all the study groups. Alteration in the levels of biochemical markers of hepatic damage like AST, ALT, ALP, Total Protein, Total Bilirubin and lipid peroxides (TBARS) were tested in both CCl4 treated and extract treated groups. CCl4 has enhanced the AST, ALT, ALP and the Lipid peroxides (TBARS) in liver. Treatment of aqueous extract of Flacourtia indica leaves (250 & 500 mg/kg) exhibited a significant protective effect by altering the serum levels of AST, ALT, ALP, Total Protein, Total Bilirubin and liver TBARS. These biochemical observations were supported by histopathological study of liver sections. From this preliminary study it has been concluded that the aqueous extract of the leaves of Flacourtia indica protects liver against oxidative damages and could be used as an effective protector against CCl4 induced hepatic damage. Our findings suggested that Flacourtia indica possessed good hepatoprotective activity